Alzheimer's disease
Conditions
Interventions
Sham rTMS group:The patient was seated in a comfortable chair with his hands rotated internally in a relaxed posture. RMT was the lowest intensity to elicit motor evoked potentials of at least 50 mV i
rTMS group:The stimulation site was again located in the left DLPFC, and the coil stem was directed 45° posterior and lateral to the sagittal plane. The distance between the center of the coil and the
Sponsors
Huashan Hospital affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age 50-85 years old, male or female; 2. Right handed; 3. Mild, moderate and severe Alzheimer's disease (AD) : all patients were diagnosed according to the diagnostic criteria for AD formulated by NINCDS/ADRD. Brain MRI examination (within 6 months) supported this diagnosis. 4. For medically treated patients, a stable dose of cholinesterase inhibitor, manluthna, or memantine was maintained for > 90 days. 5. Be able to cooperate with doctors for treatment and evaluation according to requirements; 6. The participants and their legal representatives understood and signed the informed consent; 7. The patient's life is basically or completely self-care; Inability to take care of oneself requires a relatively fixed caregiver who accompanies the patient to receive treatment every day.
Exclusion criteria
Exclusion criteria: 1. Dementia caused by systemic diseases or nervous system diseases, such as general paresis dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinson's dementia, etc. 2. Patients diagnosed with major depression or other serious mental disorders; 3. Previous history of psychotropic drug abuse or alcohol abuse that interferes with cognitive function assessment; 4. Participants in other clinical intervention research trials; 5, acute cerebrovascular disease, encephalitis, brain trauma and other acute nervous system diseases, serious heart, liver, lung, kidney or other systemic diseases, acute phase of various infections, malignant tumors; 6. There are diseases that affect clinical evaluation, including aphasia, severe hearing and visual impairment, severe dysarthria, etc. 7. Cardiac pacemaker, coronary stent, cochlear implant or other ferromagnetic material; 8. Withdrawing from the study halfway; 9, patients with any other serious medical conditions identified by the investigator that may interfere with the study process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive, ADAS-cog;Montreal Cognitive Assessment, MoCA;Mini-mental State Examination, MMSE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale, HAMA;Hamilton Depression Scale, HAMD;Pittsburgh sleep quality index, PSQI;Activity of Daily Living, ADL;Neuropsychiatric Inventory, NPI;Social Support Rating Scale, SSRS; | — |
Countries
China
Contacts
Public ContactZhou Houguang
Huashan Hospital affiliated to Fudan University
Outcome results
None listed